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Opioid use disorder (OUD) is a major public health burden. Opioids long have been 
shown to disrupt sleep and sleep disruption enhances the likelihood of addiction relapse in 
humans. The National Institutes of Health (NIH) refers to the mouse as one of the most powerful 
animal systems to study because of the genetic homologies between human and mouse. Prior to 
the present research, no studies have quantified the effect of opioids on states of sleep and 
wakefulness in mice. The current study was designed to test the hypothesis that acute 
administration of buprenorphine, morphine, or fentanyl disrupts sleep/wake architecture in 
C57BL/6J (B6) mice. Adult male mice (n = 8) were housed in a temperature-controlled 
environment and a 12:12 h light:dark cycle with ad libitum access to food and water. Mice were 
anesthetized with isoflurane for implantation of a telemeter (DSI HD-X02) and electrodes for 
wireless recording of cortical electroencephalogram (EEG) and dorsal neck muscle 
electromyogram (EMG). These signals were used to objectively quantify wakefulness, NREM 
sleep, and REM sleep in 10-s bins. Every mouse received at least one intraperitoneal injection 
(0.3 mL) each of saline (control) and an antinociceptive dose of buprenorphine, morphine, and 
fentanyl separated by one week. Each recording was scored independently by two individuals, 
one of whom was blinded to the treatment condition. Sleep scoring concordance scores were 
greater than 90%. These results, expressed as percent change from saline, summarize 64 
recordings. Buprenorphine significantly increased wakefulness (151% ;p=0.0078) and eliminated 
both NREM and REM sleep. Morphine significantly increased wakefulness (142% ;p=0.0078), 
decreased NREM sleep (-94% ;p=0.0078) and eliminated REM sleep. Fentanyl significantly 
increased wakefulness (105% ;p=0.0078), decreased NREM sleep (-68% ;p=0.0078) and 
decreased REM sleep (-89% ;p=0.0078).   
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Chapter 1: Introduction 
Opioids are effective for managing pain, but clinical1-7 and preclinical8-11 studies show 
that acutely administered opioids cause sleep disruption. Chronic opioid use has been linked to a 
number of negative effects such as disrupted sleep architecture,6 daytime fatigue,5 and 
hypersomnolence.1 Opioid use disorder (OUD) is a major burden on public health.12 Medical 
assisted therapy for OUD includes the opioids methadone, naltrexone, and buprenorphine.12 
Characterizing the sleep disruption caused by opioids is an important step towards developing 
treatments for pain with reduced unwanted side effects. 
Similar to breathing, sleep is a biological rhythm that is organized temporally13 and 
comprised of specific neurochemical and electrophysiological changes within the brain.14 
Multiple brain regions including the brain stem, hypothalamus, and basal forebrain converge to 
actively produce behavioral states of wakefulness, non-rapid eye movement (NREM) sleep, and 
rapid eye movement (REM) sleep.15,16 Cortical electroencephalographic (EEG) activity 
associated with NREM sleep is typically within the 0.5 to 4 Hz range (i.e., delta waves) and in 
REM sleep it is in the 4 to 8 Hz range (i.e., theta waves).17 Monoamines within the brain have 
long been known to promote wakefulness and cortical acetylcholine plays a major role in 
generating the active brain-states of wakefulness and REM sleep (otherwise known as 
paradoxical sleep because the EEG is similar to the EEG of wakefulness).13,18 Adenosine 
increases in metabolically active brain regions during periods of prolonged wakefulness and 
suppresses wake-promoting neurotransmitters, thereby contributing to the generation of NREM 
and REM sleep.13,18 
The brain’s electrical18 and neurochemical19 activity markedly differs between states of 
sleep and wakefulness.13 The physiological and temporal organization that produces healthy, 
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restful sleep is described as sleep architecture and provides functional metrics (i.e., latency to 
sleep onset, number of bouts of NREM sleep and REM sleep, and fragmentation of these 
episodes) for measuring sleep quality and diagnosing sleep disorders.13,14 Sleep architecture in 
adult humans can be significantly altered even after a single dose of oral opioids.2,20 Patients with 
chronic pain who are prescribed opioids report more sleep impairment than patients who are not 
prescribed opioid medications.3 Due to the addictive and deleterious side effects of opioids, it is 
not ethically possible to perform mechanistic studies in humans. To overcome these limitations, 
non-human animals are used to fill these gaps in knowledge.  
Opioids increase wakefulness and inhibit the NREM and REM phases of sleep in rats.9 In 
cat, microinjection of morphine into the nucleus of the solitary tract disrupts sleep architecture.11 
Studies of rat show that morphine administered to the basal forebrain or given systemically 
decreases cortical acetylcholine release and slows EEG activity.10 Buprenorphine has been 
shown to disrupt sleep and decrease concentrations of adenosine in sleep-regulating brain regions 
in rats.8 The C57BL/6J (B6) mouse carries special relevance, as the National Institutes of Health 
(NIH) refers to the mouse as the premier mammalian model system for biomedical research.21 
B6 mice are genetically tractable in vivo models that facilitate mechanistic investigation into a 
plethora of human illnesses.22 There is more than 90% homology between the mouse and human 
genome23 supporting the view that studies of mice can help understand normal and abnormal 
physiology and behavior in humans. Taken together, the foregoing feasibility and translational 
potential described here supports the view that studies of mice offer a powerful model for 
investigating the neurochemical and electrophysiological characteristics regulating human sleep 
and wakefulness.24  
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Buprenorphine is an opioid that acts as a partial mu-opioid receptor agonist and full 
kappa-opioid receptor antagonist.25 Buprenorphine has a longer half-life than fentanyl or 
morphine.26 By contrast, morphine and fentanyl are full mu-opioid receptor agonists. This 
pharmacological difference allows buprenorphine to be a feasible and common option for 
substitution therapy in OUD.25 However, sleep quality is severely impaired by stable 
buprenorphine or methadone treatment.3,27 Buprenorphine also causes sleep disruption that is 
associated with increased depressive symptoms in clinical patients.27 
Sleep disturbance significantly predicts the outcome of treatment for illicit drug and 
alcohol use disorder in primary care,28 and many opioids cause sleep disruption that enhances the 
likelihood of relapse.29 Sleep disruption can also delay wound healing30 and increase levels of 
inflammatory markers such as interleukin 6.31 Poor sleep quality has been indicated to exacerbate 
negative emotional states, which can lead to addiction relapse.32 Sleep disruption can also cause 
hyperalgesia (increased perception of pain), which leads to higher doses of opioids required to 
achieve the effect of antinociception.13,33 Taken together, these studies highlight the importance 
of characterizing opioid-induced sleep disruption. 
A systematic review of the literature revealed no similar studies aiming to elucidate 
whether opioids alter states of sleep and wakefulness in the B6 mouse. This study aimed to fill 
this gap in knowledge by testing the hypothesis that systemic opioid administration disrupts 





Chapter 2: Materials and Methods 
Animals 
All procedures in this study were reviewed and approved by the University of Tennessee 
Institutional Animal Care and Use Committee and were conducted in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals.34 Subjects 
included mature, male C57BL/6J (B6) mice (Stock# 000664; n = 8) purchased from the Jackson 
Laboratory. Mice were housed with littermates on arrival, and cages and litter were changed 
weekly. Mice were given one week to adapt to the laboratory and conditioned to being handled 
for an additional week before beginning experiments. They were housed in a temperature-
controlled environment and maintained in a 12:12 h light:dark cycle. Food and water were 
provided ad libitum. Teklad 8640 rodent chow was purchased from Research Diets, Inc., (New 




The mice were anesthetized with isoflurane in order to subcutaneously implant a 
telemeter (HD-X02, Data Sciences International (DSI), Minneapolis, MI.) that made it possible 
to record electroencephalogram (EEG) and electromyogram (EMG) (Fig. 1). The telemeters 
were connected to bipolar electrodes implanted in the dorsal neck muscles for recording EMG. 
An additional pair of electrodes was implanted via craniotomies above the prefrontal cortex 
(A=31; L=4; V=-2) using stereotaxic coordinates of a mouse brain atlas.35 These bipolar cortical 
electrodes were used to record the EEG. Mice also were implanted subcutaneously with a radio-
frequency identification (RFID) chip (ID-100B 1.4, Trovan, Ltd., United Kingdom) that gave 
each mouse a unique identification number. During surgery, core body temperature was 
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monitored and maintained at 37 degrees C, and respiratory rate was recorded every 5 min. At 
completion of implantation, the incision was closed, and mice were placed in a warm recovery 
chamber where they were monitored continually until they were ambulatory. All mice recovered 
without difficulty and within 24 h exhibited normal feeding and grooming behaviors. After 
telemeter implantation the mice were housed individually throughout the remainder of the study. 
The telemeters (Fig. 1), when chronically implanted wirelessly transmit recordings of 
EEG and EMG signals via antenna within the receiver pads beneath each mouse cage (Fig. 2). 
The receiver pads are connected to the DSI Matrix 2.0 (MX2) instrumentation (not pictured) via 
cables. This device facilitates communication between the implanted telemeter and the data 
acquisition computer, which was utilized to filter and analyze the transmitted signals. Once 
digitized, the EEG and EMG recordings were scored every 10 s for the duration of the recording 
as wakefulness, NREM sleep, or REM sleep. 
 
Figure 1. Illustration of a HD-X02 telemeter implanted subcutaneously in a mouse. The 
drawing schematizes that electrodes placed above the cerebral cortex and in the dorsal neck 
muscles were connected to the telemeter 
(https://www.datasci.com/solutions/neuroscience?wvideo=7d1ni1696w). Manufacturer details 






Recording States of Sleep and Wakefulness 
After a week of surgical recovery, the signal-to-noise quality of the EEG and EMG 
recordings were evaluated to ensure that they could be used to objectively score states of sleep 
and wakefulness while mice were behaving freely in their home cage. Profiles of delta and theta 
power, along with EMG amplitude, made it possible to accurately score the behavioral states of 
sleep and wakefulness in each recording. States of wakefulness were characterized by low 
amplitude EEG, the presence of maximal EMG signal (Fig. 3A), and a delta/theta ratio of 1:4.14 
EEG frequencies from 0.5 to 4 Hz (delta waves) are typically seen during NREM sleep (Fig. 
3B). EEG frequencies from 5 to 8 Hz (theta waves) are associated with REM sleep (Fig. 3C). 
These recordings created an objective index of behavioral states during each experiment.  
Figure 2.  Illustration of the experimental set up for a wireless recording of sleep and 
wakefulness from freely moving B6 mice. Each mouse’s home cage was placed on a receiver 
(black pad) numbered 1 to 4, which relayed the signal from the implanted telemeter to a 
computer in another room (not shown) where they were analyzed. This permitted the 




  Illustration of EEG and EMG signals and characteristics of the behavioral states of (A) 
wakefulness, (B) NREM sleep, and (C) REM sleep. All signals were taken from the same mouse 
during a single recording session following injection of saline. The EEG signals are represented 
in blue, and the EMG signals are shown in black. The abscissa shows three sequential 10-s 
epochs, and the ordinate shows the amplitude of the signals (µV). Wakefulness was 
characterized by low amplitude/high frequency EEG combined with high amplitude EMG. 
NREM sleep has high amplitude/low frequency EEG (i.e., slow waves) with lower amplitude 
EMG, and REM sleep has low amplitude/high frequency EEG (similar to waking) and very low 
muscle activity shown by the EMG. Considered together, the instrumentation and recordings 
illustrated by Figures 1 and 2 were used to record and objectively score states of sleep and 







Each mouse’s body weight was recorded prior to each experiment. Mean ± SD body 
weight for mice used for this study was 34.8 ± 1.97 g. Data collection started immediately after 
the mice received intraperitoneal (IP) injections (0.3 mL) of sterile saline (control) or saline 
containing antinociceptive doses of buprenorphine36 (0.3 mg/kg), morphine37 (10 mg/kg), or 
fentanyl38 (0.4 mg/kg). Recordings were performed for 4 h and began immediately post-
injection. Experiments using a subset of animals (n = 4) were conducted to quantify opioid 
effects on sleep and wakefulness for 24 h post-injection. A within-subjects design was used such 
that every mouse received at least one IP injection of saline and each opioid treatment condition, 
which was counter-balanced regarding the order of drug administration. Mice were given one 
week for a washout period between injections. Data from repeated injections of the same drug 
into the same mouse were averaged in order not to inflate degrees of freedom. After each 
injection mice were returned to their home cages, which were placed on the telemeter receiving 
pad. Use of the DSI telemeter system made it possible to obtain recordings of sleep and 
wakefulness from mice freely ambulating in their home environment. Time of day for all 
recordings was standardized to begin 1.5 h after lights on.  
Signal Processing 
The EEG and EMG recordings were analyzed using the DSI Neuroscore program. The 
Ponemah software was set to record signals at a sampling rate of 500 Hz. EEG signals were 
filtered between 0.5 and 30 Hz, and EMG signals between 10 and 100 Hz. Each 4-h and 24-h 
recording was analyzed in 10-s epochs (i.e., 4-h recording = 1,440 epochs), which were scored 
for sleep and wakefulness. Epochs that contained behavioral state transitions (i.e., transitions 
from wakefulness to NREM sleep, NREM sleep to REM sleep, etc.) were scored based on the 
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behavioral state that occurred for more than half of the epoch. The Neuroscore software created a 
fast Fourier transformation (FFT) of the EEG signal which quantified the delta and theta EEG 
power for each 10-s epoch of the recording. All recordings were double-scored, and the duplicate 
evaluators were blinded to the treatment conditions. Recordings that did not achieve a >90% 
concordance between evaluators were rescored until this criterion was reached. Microsoft Excel 
was used to plot states of wakefulness, NREM sleep, and REM sleep as a function of time across 
the 4-h recording for each injection condition (Fig. 4). 
 
Statistics Analyses 
Dependent variables of this study included percent of time spent in each behavioral state, 
number of episodes for each state, duration of the state episodes, and latency to onset of NREM 
and REM sleep. These measures were quantified as the median ± interquartile range (IQR). Each 
of these variables represents a key component of sleep architecture and thus offered insight into 
which aspects of sleep were altered by the administered opioids. Descriptive and inferential 
statistical analyses were performed using Prism 8.3.0 (GraphPad Software, San Diego, CA). The 
Wilcoxon signed rank (non-parametric) test, Analysis of variance (ANOVA), and Tukey’s 
multiple comparison test were used for post-hoc analysis. Statistical significance was shown by 




Chapter 3: Results 
3.1 Opioids altered the timing of sleep and wakefulness in B6 mice  
Systemically administered opioids disrupted the sleep/wake architecture of B6 mice as 
illustrated by Figure 4. The temporal organization of sleep was altered for all recordings 
following opioid injection that were analyzed in this study. These representative plots illustrate 
that systemically administered opioids disrupted sleep architecture relative to saline (control). 
The number of transitions and episodes for each state was decreased, as shown by fewer black 
bars for opioid conditions when compared to saline. The duration of sleep episodes was 
decreased and waking episodes were increased, which is indicated by the change in the width of 
the black bars. The latency to onset of sleep was delayed. This is illustrated by the first sleep 
episodes moving further away from time point zero following administration of fentanyl, or 
morphine, and by the elimination of sleep caused by buprenorphine administration.  
  
This figure shows the temporal organization of wakefulness (WAKE), non-rapid eye 
movement (NREM) sleep, and rapid eye movement (REM) sleep plotted as a function of time  
after systemic drug delivery. Each row represents the 4-h time course of sleep and wakefulness 
for one mouse. Each column shows injection conditions of saline (control), morphine, fentanyl, 




and buprenorphine. The abscissa of each graph represents the time in hours (h) following 
intraperitoneal injection at time point zero. The ordinate indicates the behavioral states of 
wakefulness, NREM sleep, and REM sleep. The histogram height provides information about 
whether the mouse was awake or asleep, and the width of each histogram indicates the duration 
of time spent in each state.   
 
 
3.2 Opioids altered the percent of 4-h recoding time in states of sleep and wakefulness 
The percent of time spent in each measured behavioral state as a function of the drug 
condition is summarized for 4-h recordings in Figure 5. 
 
3.3 Opioids caused disruption of sleep and wakefulness lasting up to 16 hours 
A subset of animals (n = 4) was used to quantify percent of time spent in states of 
wakefulness, NREM sleep, and REM sleep for 24 h post-injection. These studies aimed to 
determine the duration of the opioid effects on sleep and wakefulness. Sleep/wake cycles in 
mammals are closely tied to cycles of light and dark (i.e., humans are diurnal and mice are 
nocturnal), so it was important to quantify the recordings during periods of light (7:00 a.m. to 
7:00 p.m.) and dark (7:00 p.m. to 7:00 a.m.). The change in the percent of time spent in each 
measured behavioral state as a function of the drug condition is summarized for 24-h post-
injection in Figure 6.  
 
3.4 Opioids disrupted the temporal organization of 24-h sleep/wake architecture  
The time course (in 2-h intervals) for percent of time spent in each measured behavioral 
state as a function of the drug condition is summarized for 24-h post-injection in Figure 7.  
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This figure illustrates the group data for percent of time spent in behavioral states of 
sleep and wakefulness as a function of the treatment condition. The data points above each 
histogram represent data from individual mice (n = 8). Histogram height conveys the median. 
Black lines between the data points illustrate the interquartile range (IQR). (A) One-way 
ANOVA showed that mice spent significantly more time in wakefulness after injection  of each 
opioid when compared to saline (F=118.2; df=3,28; p<0.0001). (B) indicates NREM sleep was 
significantly decreased by morphine and fentanyl and was eliminated by buprenorphine 
(F=106.5; df=3,28; p<0.0001). (C) illustrates that mice spent significantly less time in REM 
sleep, which was eliminated by both morphine and buprenorphine (F=155.4; df=3,28; p<0.0001). 
Across 4 h, opioids caused an increase in wakefulness and a decrease in NREM and REM sleep 
compared with saline. Tukey’s multiple comparison test revealed significant (**p<0.0001) 
differences for all three opioid treatment conditions relative to saline during a 4-h recording.  
 
Figure 5.  
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 This figure illustrates that opioids significantly altered the percent of time spent in 
each behavioral state during the light phase, the dark phase, and across the 24-h period. Two-way 
ANOVA revealed significant main effects and an interaction due to injection condition and 
light/dark phases for percent of 24-h recording spent in behavioral states. On the ordinate of 
every graph is the percent of time spent in each behavioral state plotted as a function of injection 
condition. Histogram height represents the median and the black lines convey the IQR. The 
abscissa of each graph shows the 24-h period and both the light (7:00 a.m. to 7:00 p.m.) and dark 
Figure 6.  
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(gray shading indicating 7:00 p.m. to 7:00 a.m.) periods. (A) Two-way ANOVA revealed mice 
spent significantly more time in wakefulness following opioid injection relative to saline 
(F=42.17; df=3,24; p<0.0001); light vs dark comparison revealed a significant main effect 
(F=5.745; df=1,24; p=0.0247), and evaluation of the interaction indicated significant differences 
as a function of drug and light/dark phase (F=26.83; df=3,24; p<0.0001). (B) indicates that 
NREM sleep was significantly decreased by opioids compared to saline (F=40.02; df=3,24; 
p<0.0001). There was a significant effect of light/dark phase (F=6.533; df=1,24; p=0.0173) and a 
significant interaction between injection condition and light/dark phase (F=19.37; df=3,24; 
p<0.0001). (C) illustrates that mice exhibited significantly less REM sleep following opioid 
injection when compared with saline during the 24-h period and the light/dark cycles (F=9.482; 
df=3,24; p=0.0003). Light vs dark comparisons revealed no differences, and evaluation of the 
interaction between injection condition and light/dark phases indicated significant differences 
(F=45.04; df=3,24; p<0.0001). Across 24 h, opioids caused an increase in wakefulness and a 
decrease in NREM and REM sleep compared with saline. Tukey’s multiple comparison test 
revealed significant (*p<0.05 and **p<0.0001) differences for percent state following morphine 
and buprenorphine relative to saline for the 24-h period, though there were no differences 
following acute fentanyl administration. There were significant (**p<0.0001) differences for 
percent of time in behavioral states following all three opioid treatment conditions compared 
with saline during the light cycle. Percent of time spent in each behavioral state following 
fentanyl or buprenorphine administration was significantly (*p<0.05) different from saline 
during the dark cycle, however there were no morphine effects on sleep and wakefulness during 
the dark cycle. 
15 
 
Illustration of the time course for percent sleep and wakefulness for (n = 4) mice 
during 24-h recordings. This aids in characterizing behavioral states as altered by each of the 
four injection conditions. The differences in time course for percent state of wakefulness, NREM 
sleep, and REM sleep across a 24-h recording are plotted in 2-h time intervals for each drug 
condition. This figure illustrates 10.5 h of light, followed by 12 h of dark, and 1.5 h of light that 
comprised the 24-h recording. The data points on the time-course plot represent the median and 
the IQR. The shaded area from 10.5 h to 22.5 h post-injection indicates the dark period. Two-
way ANOVA evaluated the potential for main effects on state due to drug, time post-injection, 
Figure 7.  
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and for a drug by time interaction (A). Mice spent significantly more time in wakefulness after 
opioid injection as a function of time (F=4.77; df=11,144; p<0.0001) and drug (F=28.21; 
df=3,144; p<0.0001). There was also a significant drug by time interaction for the percent of 
time in wakefulness (F=1.842; df=33,144; p=0.0077). (B) ANOVA revealed mice spent 
significantly less time in NREM sleep as a function of time (F=7.495; df=11,144; p<0.0001) and 
drug (F=27.92; df=3,144; p<0.0001). NREM sleep was significantly decreased as a function of 
the interaction between injection condition and time (F=2.578; df=33,144; p<0.0001). (C) 
illustrates that mice spent significantly less time in REM sleep following opioid injection as a 
function of drug (F=1.897; df=3,144; p<0.0001). ANOVA revealed there was no time effect on 
REM sleep, but the drug by time interaction was significant (F=3.556; df=33,144; p<0.0001). 
Tukey’s multiple comparison test revealed significant (*p<0.05) differences in the time course of 
behavioral states following acute opioid administration when compared with saline at each 2-h 
time segment. Asterisks, color-coded utilizing the figure legend for fentanyl, morphine, and 
buprenorphine, were placed above each 2-h time interval. This illustrated  opioid treatment 
conditions that caused a significant (*p<0.05) change in sleep and wakefulness, relative to saline, 
at each 2-h period. For instance, the orange asterisks at 4-h post-injection for every measured 
behavioral state shows that buprenorphine significantly (*p<0.05) increased wakefulness 
(relative to saline in blue) and deceased both NREM and REM sleep during this 2-h interval. 
NREM sleep following fentanyl or morphine was significantly (*p<0.05) different from saline 
levels at 4 h and 6 h post-injection, respectively. After buprenorphine injection, REM sleep 
required approximately 10 h to return to saline levels. Post-administration of fentanyl or 
buprenorphine mice spent significantly (*p<0.05) more time in REM sleep (relative to saline) at 
14 h and 16 h post-injection, respectively, during the dark cycle. 
17 
 
3.5 Opioids altered the amount of time spent in states of sleep and wakefulness during 
periods of light and dark  
The percent change for  time mice spent in each measured behavioral state as a function 
of the injection condition is summarized for the light and dark cycles in Figure 8. 
 
3.6 Opioids decreased the number of episodes of wakefulness, NREM sleep, and REM sleep 
The difference in the number of episodes for each measured behavioral state as a function 
of the drug condition 4-h post-injection is summarized in Figure 9.  
 
3.7 Opioids decreased the number of episodes of sleep and wakefulness during a 24-h 
recording 
Differences in the number of episodes for each measured behavioral state as a function of 
the drug condition 24-h post-injection are summarized in Figure 10.  
Illustration of the percent change (from saline) for each measured behavioral state  Figure 8.  
18 
 
during the light and dark periods following opioid administration. The points above each  
histogram represent data from each mouse (n = 4). On the ordinate of every graph is the percent 
change relative to saline for amount of time spent in each behavioral state as a function of the 
injection condition. The top of each histogram represents the median and the black lines convey 
the IQR. The abscissa of each graph shows both the light (7:00 a.m. to 7:00 p.m.) and dark (7:00 
p.m. to 7:00 a.m.) phases. (A) One-way ANOVA showed that mice spent significantly more time 
in wakefulness as a function of drug (F=20.7; df=3,24; p<0.0001) and revealed a significant 
main effect of light/dark cycle (F=66.21; df=1,24; p<0.0001). The drug by time interaction was 
also significant regarding the time spent in wakefulness (F=16.78; df=3,24; p<0.0001). (B) 
indicates that NREM sleep was significantly decreased by opioids compared to saline (F=28.91; 
df=3,24; p<0.0001), and there was a significant main effect of light/dark period (F=16.41; 
df=1,24; p=0.0005). There was also a significant drug by time interaction for the percent of time 
in NREM sleep (F=6.634; df=3,24; p=0.002). (C) illustrates that mice spent significantly less 
time in REM sleep following opioid injection when compared to saline (F=8.672; df=3,24; 
p=0.0004). There was a significant main effect of light/dark cycle (F=77.67; df=1,24; p<0.0001) 
and drug by time interaction (F=36.01; df=3,24; p<0.0001) regarding the time in REM sleep. 
Tukey’s multiple comparison test revealed significant (*p<0.05 and **p<0.0001) differences for 
all three opioid conditions compared to saline for the light cycle. Following morphine and 
buprenorphine administration, NREM and REM were significantly (*p<0.05 and **p<0.0001) 
different from saline during the dark cycle. Fentanyl had no effect on any of the three measured 





This figure shows the decrease in the total number of waking, NREM, and REM sleep 
episodes following opioid administration when compared to saline during the 4-h recordings for 
(n = 8) mice . The total number of episodes for each behavioral state was decreased by opioids. 
The ordinate of each graph illustrates the number of episodes as a function of drug condition. 
Histogram height represents the median and the black lines convey the IQR. (A) shows that 
opioids caused a significant decrease in the number of waking episodes relative to saline 
(F=59.06; df=3,28; p<0.0001). (B) The number of NREM sleep episodes was significantly 
decreased by morphine and fentanyl and was eliminated by buprenorphine (F=64.38; df=3,28; 
p<0.0001). (C) The number of REM episodes was significantly decreased by all opioids 
(F=109.8; df=3,28; p<0.0001). REM sleep episodes were eliminated by both morphine and 
buprenorphine. Across 4 h, following opioid injection mice showed a decrease in the number of 
waking, NREM sleep, and REM sleep episodes compared with saline. Tukey’s multiple 
comparison test revealed significant (**p<0.0001) differences, relative to saline, in the number 
of episodes for every measured behavioral state following fentanyl, morphine, or buprenorphine. 
Figure 9.  
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This figure illustrates opioids significantly reduced the number of episodes for each 
behavioral state during a 24-h period, and the light and dark phases. Two-way ANOVA revealed 
significant main effects and an interaction due to injection condition and light/dark phases for the 
number of episodes of wakefulness, NREM, and REM sleep during a 24-h recording. The data 
Figure 10.  
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points above each histogram represent each mouse (n = 4). On the ordinate of every graph is the 
number of episodes for each behavioral state as a function of injection condition. Histogram 
height represents the median, and the IQR is shown by the black bars. The abscissa of each graph 
shows the 24-h period and both the light (7:00 a.m. to 7:00 p.m.) and dark (7:00 p.m. to 7:00 
a.m.) cycles, which is also represented by the shaded box. (A) shows mice exhibited significantly 
fewer waking episodes after each opioid injection when compared to saline (F=33.15; df=3,24; 
p<0.0001). There was a significant main effect of light/dark phase (F=14.91; df=1,24; p=0.0007) 
and interaction between injection condition and light/dark phase for the number of waking 
episodes (F=4.84; df=3,24; p=0.009). (B) indicates the number of NREM sleep episodes was 
significantly decreased by opioids during a 24-h recording (F=33.75; df=3,24; p<0.0001). Light 
vs dark comparisons revealed a significant main effect (F=15.52; df=1,24; p=0.0006), and 
evaluation of the interaction was also significant regarding the number of NREM sleep episodes 
(F=5.115; df=3,24; p=0.0071). (C) illustrates that mice had significantly fewer REM sleep 
episodes after each opioid injection when compared to saline (F=11.55; df=3,24; p<0.0001). 
ANOVA revealed a significant main effect of light/dark phase (F=5.38; df=1,24; p=0.0292), and 
interaction between injection condition and light/dark phase for the number of REM sleep 
episodes (F=31.15; df=3,24; p<0.0001). Across 24 h, following opioid injection mice showed a 
decrease in the number of waking, NREM sleep, and REM sleep episodes when compared with 
saline. Tukey’s multiple comparison test revealed significant (*p<0.05 and **p<0.0001) 
differences for all three opioid treatment conditions compared with saline during the light cycle 
and 24-h period. Behavioral states following administration of morphine or buprenorphine were 
significantly (*p<0.05) different from saline during the dark cycle. There was no effect of 




3.8 Opioids altered the duration of time mice spent in episodes of sleep and wakefulness 
The change in the duration of the episodes for the measured behavioral states of 
wakefulness, NREM, and REM sleep as a function of the drug condition is summarized for 4-h 
recordings in Figure 11.  
 
 
3.9 Opioids disrupted the duration of episodes of sleep and wakefulness during a 24-h 
recording 
Changes in the duration of the episodes for each behavioral state as a function of the drug 
condition are shown for the 24-h period post-injection in Figure 12.  
 
 
3.10 Opioids delayed the onset of NREM sleep and REM sleep  
The change in the latency to onset of sleep as a function of the drug condition is 
summarized for the 4-h period post-injection in Figure 13. 24-h recordings shown in Figure 14 
made it possible to quantify the sleep latency that was eliminated by morphine (i.e., REM sleep) 





This figure summarizes the difference in duration (in minutes) of states of  
wakefulness, NREM, and REM sleep following saline or opioid administration. The duration of 
the episodes for each behavioral state during a 4-h recording was disrupted by systemic opioids. 
The data points represent each mouse (n = 8). The ordinate of every graph illustrates the duration 
of the episodes (in minutes) as a function of drug represented as the median (histogram height) 
and IQR (black lines). (A) shows that compared to saline, opioids caused significantly longer 
waking episodes (F=41.35; df=3,28; p<0.0001). (B) indicates the duration of NREM sleep 
episodes was significantly decreased by morphine and these episodes were eliminated by 
buprenorphine (F=22.68; df=3,28; p<0.0001). (C) the duration of REM sleep episodes was 
significantly decreased by fentanyl and eliminated by both morphine and buprenorphine 
(F=28.98; df=3,28; p<0.0001). Across 4 h, following opioid injection mice showed an increase 
in the duration of waking episodes and a decrease in the duration of NREM and REM sleep 
episodes when compared with saline. Tukey’s multiple comparison test revealed significant 
(*p<0.05 and **p<0.0001) differences for the duration of episodes of each behavioral state 
between saline and all opioid treatment conditions. There was no effect of fentanyl on the 
duration of waking and NREM sleep episodes during a 4-h recording. 
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Illustration of the change in duration (in minutes) for each measured behavioral state 
as a function of the drug condition during the light, dark, and 24-h phases. Two-way ANOVA 
revealed  potential main effects and an interaction due to injection condition and light/dark 
phases on the duration of episodes during a 24-h period. The data points above each histogram 
represent each mouse (n = 4). On the ordinate of every graph is the duration of episodes in 
minutes for each behavioral state as a function of the injection condition. Histogram height 
represents the median, and the IQR is shown by the black bars. The abscissa of each graph shows 
the 24-h period and both the light (7:00 a.m. to 7:00 pm) and dark (7:00 pm to 7:00 a.m.) cycles, 
Figure 12.  
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which is also represented by the shaded box. (A) shows that the trend across 24 h is for acute 
opioid administration  to increase the duration of waking episodes relative to saline. The median 
(and IQR) for the duration of waking episodes following buprenorphine administration were 
calculated (and illustrated above) excluding the outlier data point at 630 minutes during the light 
cycle. Two-way ANOVA included data from every mouse and revealed no effect on the duration 
of waking episodes as a function of drug, time, or the drug by time interaction during a 24-h 
recording. (B) indicates the duration of NREM sleep episodes was significantly disrupted by 
opioids (F=10.88; df=3,24; p=0.0001), and there was a significant main effect of light  vs dark 
cycle (F=20.95; df=1,24; p=0.0001). Evaluation of the interaction between injection condition 
and light/dark phases was also significant for the duration of NREM episodes (F=3.959; df=3,24; 
p=0.02). (C) illustrates the duration of REM sleep episodes was significantly disrupted by 
opioids (F=4.177; df=3,24; p=0.0163). There was no effect of light/dark phase on the duration of 
REM sleep episodes. The interaction between injection condition and light/dark phases was also 
significant regarding the duration of REM episodes (F=13.13; df=3,24; p<0.0001). Across 24 h, 
following opioid injection mice showed an increase in the duration of waking episodes and 
decrease in the duration of NREM and REM sleep episodes when compared with saline. Tukey’s 
multiple comparison test revealed significant (*p<0.05 and **p<0.0001) differences for all three 
opioid treatment conditions relative to saline during the light cycle and 24-h period. However, 
there was no effect on the duration of episodes for each behavioral state during the dark cycle 





This figure shows the increase in latency to onset of NREM and REM sleep caused 
by acute administration of saline, fentanyl, or morphine. Wilcoxon signed rank test revealed 
opioids significantly increased the time from drug administration to the onset of sleep. 
Recordings which did not contain NREM (i.e., n = 8 post-buprenorphine and n = 2 following 
morphine) or REM sleep (i.e., n = 8 post-buprenorphine or morphine, and n = 4 following 
fentanyl) were excluded from the Fig. 13 summary. On the ordinate of every graph is the latency 
to onset of sleep (in minutes) as a function of drug represented as the median and IQR. (A) 
Wilcoxon signed rank test showed the latency to onset of NREM sleep was significantly 
increased following injection of fentanyl (Z=2.42; Mdn=141.1; p=0.0078) or morphine (Z=1.86; 
Mdn=183.7; p=0.0313) relative to saline. NREM sleep was eliminated by buprenorphine and 
during n = 2 morphine (4-h) recordings. (B) shows REM sleep was eliminated following 
injection of fentanyl in n = 4 recordings. Wilcoxon signed rank test revealed there was no change 
in the  latency to onset of REM sleep in the remaining (n = 4) recordings of sleep and 
wakefulness post-administration of fentanyl. Morphine and buprenorphine eliminated REM sleep 
in 4-h recordings of sleep of wakefulness. Across 4 h, opioid administration caused an increase 
in the latency to onset of NREM and REM sleep.  
Figure 13.  
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Illustration of the increase in latency to onset of NREM and REM sleep as a function 
of the drug condition for the 24-h recordings in (n = 4) mice. One-way ANOVA showed the 
latency to onset of NREM and REM sleep was delayed by systemic opioids. On the ordinate of 
every graph is the latency to onset of sleep (in minutes) as a function of drug. Histogram height 
represents the median and the black bars show the IQR. (A) shows a significant increase in the 
latency to NREM sleep onset following injection of opioids when compared with saline (F=22.3; 
df=3,12; p<0.0001). (B) shows latency to onset of REM sleep was significantly increased by 
fentanyl, morphine, or buprenorphine (F=28.78; df=3,12; p<0.0001). Across 24 h, following 
opioid injection mice showed an increase in latency to onset of NREM and REM sleep relative to 
saline. Tukey’s multiple comparison test revealed significant (*p<0.05 and **p<0.0001) 
differences in the latency to onset of sleep following administration of fentanyl and 
buprenorphine, respectively. Morphine had no effect on the onset to latency of NREM and REM 




Chapter 4: Discussion 
Opioids are effective for pain management. However, all opioids cause many unwanted 
side effects including respiratory depression,39,40 delayed wound healing,30 and disruption of 
sleep.1,2,6 The purpose of this study was to determine the effects of systemically administered 
morphine, fentanyl, and buprenorphine on states of sleep and wakefulness in B6 mice. The main 
finding of this study is that all measures of sleep in B6 mice were disrupted by acute opioid 
administration. Furthermore, the largest disruption in sleep was caused by buprenorphine, which 
is FDA approved for treatment for OUD.12 Previous literature has indicated that sleep disruption 
is the number one predictor of relapse for substance abuse disorders.28,29 Poor sleep quality has 
been shown to increase drug cravings,41 exacerbate negative emotional states (associated with 
relapse),32 and increase depressive symptoms.27 Sleep disruption can also cause hyperalgesia 
(increased perception of pain), which leads to higher doses of opioids required for 
antinociception.13,33 Differential effects of the three opioids on sleep are most likely due to 
pharmacokinetic and pharmacodynamic differences among these drugs, especially the half-life 
and potency.  
Based on measures of 24-h sleep architecture and time-course of behavioral states 
following opioid administration reported in this study, buprenorphine caused longer sleep 
disruption compared to fentanyl or morphine before normalizing, relative to saline. This is likely 
related to the longer half-life of buprenorphine in comparison with morphine or fentanyl.25 
Results in this study also indicate that morphine caused a larger disruption in sleep and 
wakefulness (relative to saline) than fentanyl, especially during a 24-h recording. Morphine and 
fentanyl are both full mu-opioid receptor agonists; however, fentanyl is 50 to 100-times more 
potent, has a higher intrinsic efficacy at mu-opioid receptors, and a shorter half-life.26 Morphine 
29 
 
causes a large increase in cortical histamine42 and monoamines (such as histamine) have long 
been implicated in actively promoting wakefulness.13  
Opioid-induced changes illustrated in this study created significantly different behavioral 
states based on physiological measures than normal states of sleep and wakefulness.13,18 Mice in 
this study exhibited increased ambulation accompanied by the Straub effect43 (a long-standing 
bioassay for morphine characterized by the tail pointed straight up in the air) following opioid 
administration. This finding is consistent with previous literature, which indicates that morphine 
and buprenorphine administered systemically to mice causes an increase in motor activity and in 
rats causes a loss of descending inhibition that is seen in the tail.44 Disruptions in the sleep/wake 
cycle were illustrated qualitatively by EEG/EMG signals (Fig. 3) and graphs of 4-h sleep 
architecture following saline or opioid administration (Fig. 4). Further quantitative analysis 
elucidated disruption of major elements of healthy sleep architecture including: percent of time 
spent in states of sleep and wakefulness (Fig. 5 & 6), time course and light/dark phases of sleep 
(Fig. 7 & 8), number of episodes for each behavioral state (Fig. 9 & 10), duration of the episodes 
(Fig. 11 & 12), and the latency to onset of sleep (Fig. 13 & 14). These results collectively 
indicate that systemic opioid administration disrupts sleep/wake states in B6 mice. 
 
Percent time in behavioral states was disrupted by opioids 
Opioids caused an increase in the percent of time mice spent awake and decreased the 
percent of time spent in both NREM and REM sleep (Fig. 5 & 6). Morphine eliminated NREM 
sleep and buprenorphine eliminated both NREM and REM sleep in a 4-h recording (Fig. 5). The 
measure of sleep and wakefulness during control conditions of the present study were evaluated 
relative to previously published data describing the percent of time (mean ± SD) B6 mice 
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typically spend in states of wakefulness (59.4 ± 1.8), NREM sleep (35.6 ± 1.5) and REM sleep 
(4.8 ± 0.3) during a 24-h period.45 Values reported in this study for 24-h sleep recordings 
following saline administration were within ± one standard deviation to those reported in 
previous literature. After injections of saline (control), NREM and REM sleep values were 
higher during the light cycle than during the dark cycle. This is in line with the physiology of 
these nocturnal animals. However even during the light phase, a time interval when these 
animals are typically sleeping, NREM and REM sleep were significantly decreased or eliminated 
by systemic opioid administration. Results from this study are consistent with data showing that 
patients receiving opioid treatments experience increased time awake and less overall sleep.3,4 
The present results from B6 mice are consistent with reports that morphine decreases NREM 
sleep in cats,11 and decreases NREM and REM sleep in rats9,10 and healthy humans.13 
Systemically administered buprenorphine increases time spent in wakefulness and decreases both 
NREM and REM sleep in rats.8 Such findings suggest opioid-induced disruption of restorative 
sleep13 and memory consolidation.46 Altogether, the decrease in sleep following acute 
administration of fentanyl, morphine, or buprenorphine in this study is consistent with the 
hypothesis that systemically administered opioids disrupts sleep/wake states in B6 mice. 
 
Opioids altered time course and light/dark cycle 
The present study found that systemically administered fentanyl, morphine, and 
buprenorphine altered the time course (Fig. 7) of behavioral states during the light and dark 
periods (Fig. 8). After administration of fentanyl and morphine, sleep/wake states did not return 
to control levels for 4 h and 6 h, respectively. Fentanyl and buprenorphine caused sleep 
disruption lasting 4 h and 10 h post-injection with an increase in REM sleep at 14 h and 16 h, 
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respectively, during the dark cycle (Fig. 7). These data indicated that opioid administration 
caused significantly more time in wakefulness and less time in NREM and REM sleep during the 
light cycle when compared to saline. The REM sleep inhibition caused by fentanyl and 
buprenorphine was followed by a rebound increase in REM sleep during the dark cycle (Fig. 8). 
These results are of interest relative to previous studies indicating opioid use in humans is 
associated with increased daytime sleepiness,5 poor daytime function,1 and reduced nighttime 
sleep quality.3,4  
 
Number of episodes was decreased by opioids 
Opioids decreased the number of waking, NREM, and REM sleep episodes when 
compared to saline (Fig. 9 & 10). Following fentanyl, morphine, or buprenorphine 
administration, REM sleep episodes displayed a rebound increase during the dark cycle of the 
24-h period (Fig. 10). This is likely due to decreased REM sleep episodes during the light cycle 
following opioid injection. Previous studies indicate opioid use causes abnormal sleep patterns5,6 
and disrupts multiple metrics of healthy sleep function.3,13 The number of sleep/wake episodes is 
directly relevant as a functional metric of sleep health as a biological rhythm.13,14,47  
 
The duration of individual sleep/wake episodes were disrupted by opioids   
Opioids increased the duration of waking episodes and decreased the duration of both 
NREM and REM sleep episodes in a 4-h recording (Fig. 11). Recordings that were maintained 
for 24 h post-injection revealed that opioids disrupted the duration of both NREM and REM 
sleep episodes and illustrated that the trend is for opioids to increase the duration of waking 
episodes (Fig. 12). To facilitate the most conservative statistical analysis, data from all mice 
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were included in the Two-way ANOVA for the duration of waking episodes. Differences in 
sample sizes between treatment conditions dramatically increases the type-1 error rate for 
ANOVA by violating the assumption of equal variances.48 The number of episodes for each 
measured behavioral state decreased during a 4-h recording, which resulted in more time spent in 
each state. This can also be understood as a hydraulic model (i.e., as one measure decreases, the 
other increases and vice versa) with the number of episodes. These findings are consistent with 
previous literature indicating opioid usage in humans is associated with longer periods of 
wakefulness and shorter sleep intervals.7 Such effects in humans are important because the 
duration of sleep episodes (similar to number of episodes) is one measure of restful sleep.13,14,47  
 
Opioids increased latency to onset of sleep 
This study found that opioids increased the latency to onset of sleep (Fig. 13 & 14). Mice 
required significantly more time to enter states of NREM and REM sleep after opioid injection 
compared to saline. The differences in sample sizes between saline and opioid conditions for 4-h 
recordings based on elimination of NREM and REM sleep following opioid injection limited the 
ability to perform ANOVA.48 This heterogeneity of variance required that non-parametric tests 
be used for this analysis. The Wilcoxon signed rank (non-parametric) test was utilized for 
analysis of 4-h recordings, because it compared an equal number of samples between saline and 
opioid treatment conditions in this model (i.e., 4 h recordings following injection saline versus 
fentanyl or morphine recordings, which contained NREM or REM sleep) and was unencumbered 
by the differences in sample size.49 Buprenorphine administered systemically causes increased 
sleep latency in rats8 and opioid use in humans is associated with increased sleep latency.3,7 
Delayed sleep latency is commonly associated with poor sleep quality and sleep disorders such 
as insomnia and narcolepsy.50  
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Limitations & Future Directions  
Limitations of this study include use of only adult male mice, and it is well understood 
that there are gender and age differences in sleep quality and in sleep disorders.51,52 This study 
chose to model clinical application of opioids by way of systemic drug delivery. The present 
results encourage future studies that use chronic administration of opioids. Sleep disturbance can 
increase over time during methadone treatment for OUD7 and chronic opioid administration is 
common for management of cancer pain. The present study was also limited to studying the B6 
line of mice. Another advantage of using mice is the availability of transgenic lines to model 
various diseases. The present results encourage the use of obese mice that lack leptin or have 
disrupted leptin receptors. In addition to functioning as a satiety factor, leptin status alters the 
antinociceptive effects of opioids.53 Finally, the present results also encourage future studies that 
aim to evaluate dose-response relationships for the effects of fentanyl, morphine, and 
buprenorphine on NREM and REM sleep. 
Despite the foregoing limitations, the present findings provide novel evidence that 
opioids cause sleep disruption in B6 mice that are similar to the sleep disruption caused by 
opioids in humans. These similar opioid effects are consistent with the close homology between 
the human and B6 mouse genome. Considered together, the results support the likelihood that 
studies of opioid effects using the B6 mouse will help provide a better understanding of the 
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